I don't think it's expensive at all compared to the size of their addressable market, and given their positioning and lack of significant competitors. It could easily be re-rated to $2B -$3B in comiing weeks as their revenue timeline comes into better focus. Should be Q4 2016 for China (4592).
FG-3019 data very, very strong. 3/3 panreatic cancer patients able to have resections after 60 days. I know it's early, but that is stellar.
Along with proven efficacy of 4592, no real competition (GSK stuck in phase 2) seemingly no need for additional raises, FGEN seems ready to have a really good '16 and '17. I don't see how this thing isn't going to the 40's next year, and potentially a lot higher than that moving forward.
It could do an RCPT performance, imo. GL